BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Nuevocor Receives FDA IND Clearance to Advance NVC-001 Gene Therapy for LMNA-Related Dilated Cardiomyopathy

LMNA-related dilated cardiomyopathy (LMNA DCM) is one of the most aggressive forms of DCM, affecting approximately 100,000 individuals in the United...

June 11, 2025 | News

Neowise Licenses TCR Technology to BeOne Medicines for Off-the-Shelf iPSC-Based Cell Therapy Development

Neowise Biotechnology ("Neowise"), a pioneering company focused on the development of TCR-T cell therapies for solid tumors, announced today that it has en...

June 10, 2025 | News

YolTech Therapeutics Receives FDA IND Clearance for In Vivo Base Editing Therapy YOLT-101

YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, announced that the U.S. Food and Drug ...

June 09, 2025 | News

Elpis Biopharmaceuticals and Singapore General Hospital Partner to Advance Next-Gen CAR-γδT Cell Therapies for AML and Multiple Myeloma

Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today announced entry into ...

June 05, 2025 | News

JW Therapeutics Secures Macao Approval for CAR-T Therapy Carteyva®, Marking First Overseas Market Entry

JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunother...

June 05, 2025 | News

XellSmart Advances Global Leadership in iPSC-Derived Cell Therapies for CNS Disorders

XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell the...

June 03, 2025 | News

AccurEdit’s ART001 Becomes First China-Developed Gene Editing Therapy to Receive FDA RMAT Designation

AccurEdit Therapeutics announced that its internally developed in vivo gene editing therapy ART001 has been granted a Regenerative Medi...

May 30, 2025 | News

CorestemChemon's Neuronata-R® Shows Promising Efficacy in Early-Stage ALS, Sets Sights on Accelerated FDA Approval

Neuronata-R®, an autologous bone marrow-derived mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis (ALS), has demonstrated meaningfu...

May 30, 2025 | News

Gene Weaver Secures Gates Foundation Grant to Advance Next-Gen Gene Insertion Platform for Affordable Therapeutics

Gene Weaver Ltd (Gene Weaver), a biology technology innovator, has received $515,214 from the Gates Foundation to support the development of a n...

May 29, 2025 | News

UniXell Biotech Initiates China’s First iPSC-Based Cell Therapy Trial for Parkinson’s Disease

Shanghai UniXell Biotechnology Co., Ltd. (UniXell Biotech), a biotech company dedicated to innovative cell therapies, announced the successful first admini...

May 26, 2025 | News

Porton Advanced and TongEYE Partner to Accelerate iPSC-Derived Cell Therapy for Blinding Eye Diseases

Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleas...

May 23, 2025 | News

KFSHRC and Cellenkos Join Forces to Launch First Saudi-U.S. Clinical Trials for Treg Cell Therapies

KFSHRC to lead Clinical Trials Targeting Aplastic Anemia and Graft vs. Host Disease Cellenkos to Support Local Cell and Gene Therapy Manufacturing at&nb...

May 23, 2025 | News

Waters Corporation Acquires Halo Labs to Advance Analytical Capabilities for Cell and Gene Therapy Development

Waters Corporation announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count i...

May 22, 2025 | News

AGC Biologics Partners with Quell Therapeutics to Advance Treg Cell Therapies for Immune Disorders

-AGC Biologics, your friendly CDMO expert, announced a partnership with Quell Therapeutics (“Quell”), a clinical-stage bio...

May 19, 2025 | News

Stay Connected